124 Chapter 3 88. De Angelis V, Breda A. Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? Blood Transfus. 2013;11(Suppl 4):s132-s137. 89. Rautonen J. Self-sufficiency, free trade and safety. Biologicals. 2010; 38(1):97-99. 90. Bruins B. Kamerbrief over voortgangsbrief geneesmiddelenbeleid. [Governmental report]. 2018. Accessed May 20, 2019. https:// www.rijksoverheid.nl/binaries/rijksoverheid/documenten/ kamerstukken/2018/12/20/kamerbrief-over-voortgangsbrief- geneesmiddelenbeleid/kamerbrief-over-voortgangsbrief- geneesmiddelenbeleid.pdf 91. Ministerie van Volksgezondheid WeS. Kamerbrief over overheveling geneesmiddelen per 2022. [Governmental report], 2021. Accessed September 1, 2021. https://www. rijksoverheid.nl/documenten/ kamerstukken/2021/04/21/kamerbrief-over-overheveling- geneesmiddelen-per-2022 92. Modell V, Knaus M, Modell F, Roifman C, Orange J, Notarangelo LD. Global overview of primary immunodeficiencies: a report from Jef- frey Modell centers worldwide focused on diagnosis, treatment, and discovery. Immunol Res. 2014;60(1):132-144. 93. Srinivasa BT, Alizadehfar R, Desrosiers M, Shuster J, Pai NP, Tsoukas CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779-786. 94. Stonebraker JS, Hajjar J, Orange JS. Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA. Vox Sang. 2018;113:430-440. 95. Stonebraker JS, Farrugia A, Gathmann B, Orange JS. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014;34(2):233-244. 96. Lagasse C, Hatton RC, Pyles E. A survey of intravenous immune globulin (IVIG) dosing strategies. Ann Pharmacother. 2015;49(2):254-257. 97. Kerr J, Quinti I, Eibl M, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014;5:629. 98. Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol. 2017;188(3):353-362. 99. Yokoyama K, Hattori N. Management of myasthenia gravis in daily practice for general neurologists and healthcare professionals. Clin Exp Neuroimmunol. 2017;8(2):162-170. 100. The Marketing Research Bureau I. IBPN March2020. Marketing Research Bureau; 2020. 101. Ben Mkaddem S, Benhamou M, Monteiro RC. Understanding fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front Immunol. 2019;10:811. 102. Kaur MN, Arnold DM, Heddle NM, et al. Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Adv. 2022;6(3): 785-792.
RkJQdWJsaXNoZXIy MTk4NDMw